Your browser doesn't support javascript.
loading
A phase 1 trial utilizing TMI with fludarabine-melphalan in patients with hematologic malignancies undergoing second allo-SCT.
Tran, Misha C; Hasan, Yasmin; Wang, Amy; Yenice, Kamil; Partouche, Julien; Stock, Wendy; Larson, Richard A; Kosuri, Satyajit; LaBelle, James L; Kline, Justin; Riedell, Peter A; Artz, Andrew S; Weichselbaum, Ralph; Bishop, Michael R; Aydogan, Bulent; Liu, Hongtao.
Afiliación
  • Tran MC; Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL.
  • Hasan Y; Department of Radiation & Cellular Oncology, University of Chicago, Chicago, IL.
  • Wang A; Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL.
  • Yenice K; Department of Radiation & Cellular Oncology, University of Chicago, Chicago, IL.
  • Partouche J; Department of Radiation & Cellular Oncology, University of Chicago, Chicago, IL.
  • Stock W; Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL.
  • Larson RA; Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL.
  • Kosuri S; Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL.
  • LaBelle JL; Department of Pediatrics, Section of Hematology, University of Chicago, Chicago, IL.
  • Kline J; Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL.
  • Riedell PA; Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL.
  • Artz AS; Gehr Family Center for Leukemia Research, City of Hope, Duarte, CA.
  • Weichselbaum R; Department of Radiation & Cellular Oncology, University of Chicago, Chicago, IL.
  • Bishop MR; Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL.
  • Aydogan B; Department of Radiation & Cellular Oncology, University of Chicago, Chicago, IL.
  • Liu H; Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL.
Blood Adv ; 7(3): 285-292, 2023 02 14.
Article en En | MEDLINE | ID: mdl-35851593
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Trasplante de Células Madre Hematopoyéticas / Neoplasias Hematológicas Límite: Humans Idioma: En Revista: Blood Adv Año: 2023 Tipo del documento: Article País de afiliación: Israel
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Trasplante de Células Madre Hematopoyéticas / Neoplasias Hematológicas Límite: Humans Idioma: En Revista: Blood Adv Año: 2023 Tipo del documento: Article País de afiliación: Israel